Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma

Quantitative biopsy pathology with prostate specific antigen significantly improves the prediction of pathologic stage in patients with clinically localized prostate carcinoma (PCa). The authors recently reported a computational model for predicting patient specific likelihood of organ confinement of PCa using biopsy pathology and clinical data. The current study validates the initial models and presents an new, improved tool for clinical decision making.

[1]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[2]  A. Partin,et al.  Ability of sextant biopsies to predict radical prostatectomy stage. , 1998, Urology.

[3]  U Pichlmeier,et al.  A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. , 2001, The Journal of urology.

[4]  P. Walsh,et al.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. , 2002, The Journal of urology.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[7]  M. Miller,et al.  Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. , 1998, Urology.

[8]  R W Veltri,et al.  Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. , 2000, Urology.

[9]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[10]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[11]  A. Haese*,et al.  Stage Migration in Clinically Localized Prostate Cancer , 2000, European Urology.

[12]  Robert W Veltri,et al.  Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. , 2002, The Journal of urology.

[13]  R T Vollmer,et al.  Predicting the pathology results of radical prostatectomy from preoperative information , 1998, Cancer.

[14]  A. D'Amico,et al.  Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. , 2000, Urology.

[15]  D. Lubeck,et al.  Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. , 2001, The Journal of urology.

[16]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[17]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[18]  Daan Brandenbarg.  The National. , 1892 .

[19]  M W Kattan,et al.  A catalog of prostate cancer nomograms. , 2001, The Journal of urology.

[20]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[21]  R W Veltri,et al.  Prediction of prostate carcinoma stage by quantitative biopsy pathology , 2001, Cancer.

[22]  J. Cheville,et al.  The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. , 2000, The Journal of urology.

[23]  R. Ho,et al.  The National Cancer Data Base report on longitudinal observations on prostate cancer , 1996, Cancer.

[24]  R. Veltri,et al.  The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. , 1998, Seminars in urologic oncology.

[25]  M W Kattan,et al.  Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.

[26]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[27]  D C Young,et al.  An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. , 1996, The Journal of urology.

[28]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[29]  R. Millikan,et al.  Update of the NCCN guidelines for treatment of prostate cancer. , 1997, Oncology.

[30]  O. Brawley,et al.  Prostate Cancer Incidence and Mortality Rates among White and Black Men , 1997, Epidemiology.

[31]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.